DDR2 and hepatocellular carcinoma: We hope to collect and include HCC patients receiving ICI treatment in future research and further verify the influence of DDR molecular type (DDR 1 and DDR2) and the DDR score on the outcomes of HCC patients receiving immunotherapy.